Anti-cardiolipin antibodies are a heterogeneous group of antibodies directed towards negatively charged phospholipids. Of the various tests available for the detection of antiphospholipid antibodies, the anti-cardiolipin antibody test has been recognised as the method of choice.
The presence of antiphospholipid (aPL) antibodies and its cofactor β2-glycoprotein I help to identify patients at risk for antiphospholipid syndrome (APS). APS may involve venous and/or arterial thrombosis, thrombocytopenia and recurrent foetal loss. Significantly raised IgA and IgM anti-cardiolipin antibodies are associated with thrombotic events (although not to the same extent as IgG). All three isotypes should be individually assessed when evaluating patients in whom APS is suspected.
AUTOZYMETM ACL is for the quantitative detection of anti-cardiolipin IgA, IgG or IgM autoantibodies in human sera or plasma to aid the diagnosis of antiphospholid syndrome (APS) in conjunction with other laboratory tests and clinical findings. It employs a unique antigen-coated microwell technology, which is ideal for the batch screening of large and small numbers of samples for ACL. The method utilises a non-competitive sandwich enzyme immunoassay system.
AUTOZYMETM ACL, anti-cardiolipin IgA, IgG and IgM Elisa assays provide excellent quantification, ideal for routine use on Elisa processors.
- Antigen: high purity cardiolipin and ß2-glycoproetin 1cofactor
- Calibration: 6 calibrators (quantitative), to internationally recognised Reference Standards IRP 97/656 (IgG) from Dr E N Harris, Louisville, USA, and HCAL (IgG) / EY2C9 (IgM)
- Serum samples, Dilution: 1/100 (10μl sample+ 990μl diluent)
- No interference from Bilirubin, Haemoglobin, Lipids, Ascorbic Acid
- Assay Time: 30’, 30’ 30
Z4496: AUTOZYMETM ACL IgA
Z4596: AUTOZYMETM ACL IgG
Z4696: AUTOZYMETM ACL IgM
Download the datasheet
These assays are complemented with assays for anti-β2-glycoprotein 1, phosphatidyserine, oxLDL antibodies and annexin-V.